Sanofi Quarterly Balance Sheets Chart
Quarterly
|
Annual
Sanofi Quarterly Balance Sheets Table
Quarterly
|
Annual
Unit: USD | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2017-12-31 | 2016-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2005-12-31 | 2004-12-31 | 2003-12-31 | 2002-12-31 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
property, plant and equipment | 10,160 | 9,869 | 10,028 | 9,365 | 9,579 | 10,019 | 10,750 | 8,155 | 7,830 | 6,961 | 6,538 | 6,184 | 5,886,000,000 | ||
right-of-use assets | 1,654 | 1,815 | 1,948 | 1,198 | |||||||||||
goodwill | 49,404 | 49,892 | 48,056 | 44,364 | 40,264 | 40,287 | 38,079 | 31,932 | 29,733 | 28,163 | 27,199 | 30,234 | 23,475,000,000 | 134,000,000 | |
other intangible assets | 24,319 | 21,640 | 21,407 | 18,421 | 13,080 | 10,879 | 23,639 | 12,479 | 1,161,000,000 | ||||||
investments accounted for using the equity method | 424 | 677 | 250 | 201 | 2,863 | ||||||||||
other non-current assets | 3,218 | 3,095 | 3,127 | 2,734 | 3,364 | 2,820 | |||||||||
non-current income tax assets | 188 | 242 | 175 | 248 | |||||||||||
deferred tax assets | 6,427 | 5,381 | 4,598 | 4,212 | 4,290 | 4,669 | 3,633 | 3,051 | 2,912 | 2,920 | 2,912 | 3,095 | |||
non-current assets | 95,794 | 92,611 | 89,589 | 80,743 | 73,440 | 71,564 | 79,307 | 58,185 | 56,175 | 56,584 | 59,361 | 73,537 | |||
inventories | 9,666 | 8,960 | 8,715 | 8,352 | 6,816 | 6,892 | 6,051 | 5,020 | 4,444 | 3,590 | 3,729 | 3,430 | 3,058,000,000 | 823,000,000 | |
accounts receivable | 8,433 | 8,424 | 7,568 | 7,491 | 7,216 | 7,311 | 8,042 | 6,507 | 6,015 | 5,303 | 4,904 | 5,021 | 4,501,000,000 | 1,311,000,000 | |
other current assets | 3,455 | 3,532 | 3,571 | 2,737 | 2,005 | 2,211 | 2,401 | 2,000 | 2,104 | 1,881 | 2,126 | 2,434 | 2,476,000,000 | 854,000,000 | |
current income tax assets | 391 | 374 | 612 | 1,208 | |||||||||||
cash and cash equivalents | 8,710 | 12,736 | 10,098 | 13,915 | 10,315 | 10,273 | 4,124 | 6,465 | 4,692 | 4,226 | 1,711 | 1,249 | |||
current assets | 30,655 | 34,026 | 30,564 | 33,703 | 26,352 | 26,687 | 20,791 | 20,043 | 17,532 | 15,403 | 12,553 | 13,121 | |||
assets held for sale or exchange | 15 | 85 | 89 | 83 | 34 | 6,421 | 67 | 7,036 | 6,342 | ||||||
total assets | 126,464 | 126,722 | 120,242 | 114,529 | 99,826 | 104,672 | 100,165 | 85,264 | 80,049 | 71,987 | 71,914 | 86,658 | 76,755,000,000 | 9,749,000,000 | 9,459,000,000 |
f-2 | |||||||||||||||
equity attributable to equity holders of sanofi | 58,089 | ||||||||||||||
equity attributable to non-controlling interests | 169 | ||||||||||||||
total equity | 58,258 | 48,446 | 45,071 | 44,719 | |||||||||||
long-term debt | 14,326 | 5,961 | 4,173 | 3,734 | 8,638,000,000 | 65,000,000 | |||||||||
non-current liabilities related to business combinations and to non-controlling interests | 1,026 | ||||||||||||||
non-current provisions and other non-current liabilities | 9,154 | ||||||||||||||
deferred tax liabilities | 1,605 | 4,933 | 5,668 | 6,935 | |||||||||||
non-current liabilities | 26,111 | 19,205 | 17,571 | 17,526 | |||||||||||
accounts payable | 4,633 | 2,654 | 2,791 | 2,749 | 2,765,000,000 | 596,000,000 | |||||||||
current liabilities related to business combinations and to non-controlling interests | 343 | ||||||||||||||
current provisions and other current liabilities | 9,206 | ||||||||||||||
short-term debt and current portion of long-term debt | 1,275 | 2,866 | 1,833 | 2,207 | |||||||||||
current liabilities | 15,457 | 10,965 | 9,345 | 9,669 | |||||||||||
liabilities related to assets held for sale or exchange | 1,433 | ||||||||||||||
total equity and liabilities | 99,826 | ||||||||||||||
investments in associates and joint ventures | 2,890 | 807 | 924 | ||||||||||||
consolidated balance sheets – liabilities and equity | |||||||||||||||
assets | |||||||||||||||
non-current financial assets | 2,399 | 1,644 | |||||||||||||
current financial assets | 173 | 51 | |||||||||||||
in accordance with ifrs 3 (business combinations), sanofi-aventis adjusted the values of certain identifiable assets and liabilities of merial during the purchase price allocation period (see note d.1.). | |||||||||||||||
intangible assets | 13,747 | 15,260 | 19,182 | 30,229 | |||||||||||
investments in associates | 955 | 2,459 | 2,493 | 2,477 | |||||||||||
financial assets — non-current | 998 | 821 | |||||||||||||
financial assets — current | 277 | 403 | |||||||||||||
liabilities & equity | |||||||||||||||
equity attributable to equity holders of the company | 48,188 | 44,866 | 44,542 | ||||||||||||
minority interests | 258 | 205 | 177 | 359,000,000 | 17,000,000 | ||||||||||
provisions and other non-current liabilities | 8,311 | 7,730 | 6,857 | ||||||||||||
other current liabilities | 5,445 | 4,721 | 4,713 | 4,852,000,000 | 1,599,000,000 | ||||||||||
total liabilities & equity | 80,049 | 71,987 | 71,914 | ||||||||||||
assets held for sale | 676 | ||||||||||||||
liabilities related to assets held for sale | |||||||||||||||
financial assets – non-current | 1,037 | 1,318 | |||||||||||||
financial assets – current | 83 | 311 | |||||||||||||
as allowed under ifrs 3, sanofi-aventis has revised certain preliminary estimates of the aventis purchase price allocation within the permitted 12-month period. | |||||||||||||||
patents, licenses and other intangibles | 29,600,000,000 | ||||||||||||||
long-term investments | |||||||||||||||
equity investees | 2,404,000,000 | ||||||||||||||
other investments and advances | 11,000,000 | ||||||||||||||
other long-term investments | 929,000,000 | 73,000,000 | |||||||||||||
total fixed assets | 62,305,000,000 | 2,712,000,000 | 2,899,000,000 | ||||||||||||
deferred income taxes | 1,925,000,000 | 472,000,000 | 484,000,000 | ||||||||||||
short-term investments and deposits | 958,000,000 | 2,944,000,000 | |||||||||||||
cash | 1,532,000,000 | 144,000,000 | |||||||||||||
in millions of euros | |||||||||||||||
liabilities and shareholders’ equity | |||||||||||||||
shareholders’ equity | |||||||||||||||
share capital | 2,823,000,000 | 1,465,000,000 | |||||||||||||
additional paid in capital and reserves | 39,377,000,000 | 2,971,000,000 | |||||||||||||
net income for the period | 1,759,000,000 | ||||||||||||||
cumulative translation adjustment | |||||||||||||||
total shareholders’ equity | 35,574,000,000 | 6,035,000,000 | |||||||||||||
other equity instruments | 16,000,000 | ||||||||||||||
provisions and other long-term liabilities | 5,768,000,000 | 786,000,000 | |||||||||||||
short-term debt | 7,388,000,000 | 351,000,000 | |||||||||||||
total liabilities and shareholders’ equity | 76,755,000,000 | 9,459,000,000 | |||||||||||||
inventories, accounts receivable & other current assets | 3,187,000,000 | ||||||||||||||
short-term investments and deposits, cash | 3,378,000,000 | ||||||||||||||
gross | 1,989,000,000 | ||||||||||||||
accumulated depreciation | |||||||||||||||
net | 1,395,000,000 | ||||||||||||||
investments in/advances to equity investees | 109,000,000 | ||||||||||||||
investments in/advances to non-consolidated companies | 27,000,000 |
We provide you with 20 years of balance sheets for Sanofi stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Sanofi. Explore the full financial landscape of Sanofi stock with our expertly curated balance sheets.
The information provided in this report about Sanofi stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.